These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 24444350)

  • 1. Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose.
    Sholukh AM; Byrareddy SN; Shanmuganathan V; Hemashettar G; Lakhashe SK; Rasmussen RA; Watkins JD; Vyas HK; Thorat S; Brandstoetter T; Mukhtar MM; Yoon JK; Novembre FJ; Villinger F; Landucci G; Forthal DN; Ratcliffe S; Tuero I; Robert-Guroff M; Polonis VR; Bilska M; Montefiori DC; Johnson WE; Ertl HC; Ruprecht RM
    Retrovirology; 2014 Jan; 11():8. PubMed ID: 24444350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus.
    Lakhashe SK; Byrareddy SN; Zhou M; Bachler BC; Hemashettar G; Hu SL; Villinger F; Else JG; Stock S; Lee SJ; Vargas-Inchaustegui DA; Cofano EB; Robert-Guroff M; Johnson WE; Polonis VR; Forthal DN; Loret EP; Rasmussen RA; Ruprecht RM
    Vaccine; 2014 Nov; 32(48):6527-36. PubMed ID: 25245933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge.
    Sholukh AM; Watkins JD; Vyas HK; Gupta S; Lakhashe SK; Thorat S; Zhou M; Hemashettar G; Bachler BC; Forthal DN; Villinger F; Sattentau QJ; Weiss RA; Agatic G; Corti D; Lanzavecchia A; Heeney JL; Ruprecht RM
    Vaccine; 2015 Apr; 33(17):2086-95. PubMed ID: 25769884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
    Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pre-existing neutralizing antibody mitigates B cell dysregulation and enhances the Env-specific antibody response in SHIV-infected rhesus macaques.
    Jaworski JP; Bryk P; Brower Z; Zheng B; Hessell AJ; Rosenberg AF; Wu TT; Sanz I; Keefer MC; Haigwood NL; Kobie JJ
    PLoS One; 2017; 12(2):e0172524. PubMed ID: 28222180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Live-virus exposure of vaccine-protected macaques alters the anti-HIV-1 antibody repertoire in the absence of viremia.
    Bachler BC; Humbert M; Lakhashe SK; Rasmussen RA; Ruprecht RM
    Retrovirology; 2013 Jun; 10():63. PubMed ID: 23800339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques.
    Jaworski JP; Kobie J; Brower Z; Malherbe DC; Landucci G; Sutton WF; Guo B; Reed JS; Leon EJ; Engelmann F; Zheng B; Legasse A; Park B; Dickerson M; Lewis AD; Colgin LM; Axthelm M; Messaoudi I; Sacha JB; Burton DR; Forthal DN; Hessell AJ; Haigwood NL
    J Virol; 2013 Oct; 87(19):10447-59. PubMed ID: 23885083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunization with wild-type or CD4-binding-defective HIV-1 Env trimers reduces viremia equivalently following heterologous challenge with simian-human immunodeficiency virus.
    Sundling C; O'Dell S; Douagi I; Forsell MN; Mörner A; Loré K; Mascola JR; Wyatt RT; Karlsson Hedestam GB
    J Virol; 2010 Sep; 84(18):9086-95. PubMed ID: 20610729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. R5 clade C SHIV strains with tier 1 or 2 neutralization sensitivity: tools to dissect env evolution and to develop AIDS vaccines in primate models.
    Siddappa NB; Watkins JD; Wassermann KJ; Song R; Wang W; Kramer VG; Lakhashe S; Santosuosso M; Poznansky MC; Novembre FJ; Villinger F; Else JG; Montefiori DC; Rasmussen RA; Ruprecht RM
    PLoS One; 2010 Jul; 5(7):e11689. PubMed ID: 20657739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge.
    Malherbe DC; Mendy J; Vang L; Barnette PT; Reed J; Lakhashe SK; Owuor J; Gach JS; Legasse AW; Axthelm MK; LaBranche CC; Montefiori D; Forthal DN; Park B; Wilson JM; McLinden JH; Xiang J; Stapleton JT; Sacha JB; Haynes BF; Liao HX; Ruprecht RM; Smith J; Gurwith M; Haigwood NL; Alexander J
    J Virol; 2018 Jan; 92(2):. PubMed ID: 29093095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying
    Scinto HB; Gupta S; Thorat S; Mukhtar MM; Griffiths A; Delgado J; Plake E; Vyas HK; Strickland A; Byrareddy SN; Montefiori DC; LaBranche C; Pal R; Treece J; Orndorff S; Ferrari MG; Weiss D; Chenine AL; McLinden R; Michael N; Kim JH; Robb ML; Rerks-Ngarm S; Pitisuttithum P; Nitayaphan S; Ruprecht RM
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29743361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
    Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
    J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
    Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP
    Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.
    Bolton DL; Pegu A; Wang K; McGinnis K; Nason M; Foulds K; Letukas V; Schmidt SD; Chen X; Todd JP; Lifson JD; Rao S; Michael NL; Robb ML; Mascola JR; Koup RA
    J Virol; 2016 Feb; 90(3):1321-32. PubMed ID: 26581981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a tier 1 R5 clade C simian-human immunodeficiency virus as a tool to test neutralizing antibody-based immunoprophylaxis.
    Siddappa NB; Hemashettar G; Wong YL; Lakhashe S; Rasmussen RA; Watkins JD; Novembre FJ; Villinger F; Else JG; Montefiori DC; Ruprecht RM
    J Med Primatol; 2011 Apr; 40(2):120-8. PubMed ID: 21044092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of neutralizing antibodies against tier 2 human immunodeficiency virus 1 in rhesus macaques infected with tier 1B simian/human immunodeficiency virus.
    Himeno A; Ishida Y; Mori H; Matsuura K; Kikukawa M; Sakawaki H; Miura T
    Arch Virol; 2019 May; 164(5):1297-1308. PubMed ID: 30820667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of a multigenic protein vaccine containing multimeric HIV gp160 against heterologous SHIV clade C challenges.
    Rasmussen RA; Ong H; Song R; Chenine AL; Ayash-Rashkovsky M; Hu SL; Polacino P; Else JG; Novembre FJ; Ruprecht RM;
    AIDS; 2007 Sep; 21(14):1841-8. PubMed ID: 17721091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection.
    Curtis AD; Saha PT; Dennis M; Berendam SJ; Ramasubramanian P; Cross KA; Alam SM; Ferrari G; Kozlowski PA; Fouda GG; Hudgens MG; Van Rompay KKA; Pollara J; Permar SR; De Paris K
    mSphere; 2022 Feb; 7(1):e0083921. PubMed ID: 35196125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
    Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
    J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralization-sensitive R5-tropic simian-human immunodeficiency virus SHIV-2873Nip, which carries env isolated from an infant with a recent HIV clade C infection.
    Siddappa NB; Song R; Kramer VG; Chenine AL; Velu V; Ong H; Rasmussen RA; Grisson RD; Wood C; Zhang H; Kankasa C; Amara RR; Else JG; Novembre FJ; Montefiori DC; Ruprecht RM
    J Virol; 2009 Feb; 83(3):1422-32. PubMed ID: 19019970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.